StockData
Seres Therapeutics, Inc. logo

Seres Therapeutics, Inc. (MCRB) stock

MCRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$1.44+0.03 (+2.13%)

Close on Nov 18, 2026Market cap $14.32MP/E –Yield –

Seres Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Seres Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$84.03M. For fiscal 2025 it was -$93.97M. The highest annual figure on record is -$6.05M in fiscal 2013.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$93.97M–
FY2024Dec 31, 2024-$121.32M–
FY2023Dec 31, 2023-$195.10M–
FY2022Dec 31, 2022-$179.91M–
FY2021Dec 31, 2021-$64.49M–
FY2020Dec 31, 2020-$88.13M–
FY2019Dec 31, 2019-$71.88M–
FY2018Dec 31, 2018-$100.28M–
FY2017Dec 31, 2017-$91.40M–
FY2016Dec 31, 2016-$92.84M–
FY2015Dec 31, 2015-$54.86M–
FY2014Dec 31, 2014-$15.08M–
FY2013Dec 31, 2013-$6.05M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$21.27M–
Q1 FY2026Mar 31, 2026-$20.91M–
Q4 FY2025Dec 31, 2025-$19.38M–
Q3 FY2025Sep 30, 2025-$22.48M–
Q2 FY2025Jun 30, 2025-$24.88M–
Q1 FY2025Mar 31, 2025-$27.24M–
Q4 FY2024Dec 31, 2024-$28.84M–
Q3 FY2024Sep 30, 2024-$29.17M–
Q2 FY2024Jun 30, 2024-$28.87M-158.3%
Q1 FY2024Mar 31, 2024-$34.44M–
Q4 FY2023Dec 31, 2023-$37.02M–
Q3 FY2023Sep 30, 2023-$44.59M–
Q2 FY2023Jun 30, 2023$49.52M–
Q1 FY2023Mar 31, 2023-$70.57M–
Q4 FY2022Dec 31, 2022-$1.73M–
Q3 FY2022Sep 30, 2022-$59.11M-186.4%
Q2 FY2022Jun 30, 2022-$63.33M–
Q1 FY2022Mar 31, 2022-$55.75M–
Q4 FY2021Dec 31, 2021-$49.43M–
Q3 FY2021Sep 30, 2021$68.41M–
Q2 FY2021Jun 30, 2021-$48.14M–
Q1 FY2021Mar 31, 2021-$35.33M–
Q4 FY2020Dec 31, 2020-$17.90M–
Q3 FY2020Sep 30, 2020-$30.00M–
Q2 FY2020Jun 30, 2020-$20.55M–
Q1 FY2020Mar 31, 2020-$19.69M–
Q4 FY2019Dec 31, 2019-$19.19M–
Q3 FY2019Sep 30, 2019-$17.18M–
Q2 FY2019Jun 30, 2019-$10.95M–
Q1 FY2019Mar 31, 2019-$24.55M–
Q4 FY2018Dec 31, 2018-$21.67M–
Q3 FY2018Sep 30, 2018-$22.21M–
Q2 FY2018Jun 30, 2018-$28.14M–
Q1 FY2018Mar 31, 2018-$28.27M–
Q4 FY2017Dec 31, 2017-$29.78M–
Q3 FY2017Sep 30, 2017-$7.31M–
Q2 FY2017Jun 30, 2017-$28.42M–
Q1 FY2017Mar 31, 2017-$25.89M–
Q4 FY2016Dec 31, 2016-$25.69M–
Q3 FY2016Sep 30, 2016-$19.10M–

More Seres Therapeutics figures

See a number that looks wrong?